HK1132739A1 - -甲基- -甲基- -酮- -喹啉- -基- -二氫-咪唑並 喹啉- -基 -苯基 -丙腈之甲苯磺酸鹽晶體 - Google Patents
-甲基- -甲基- -酮- -喹啉- -基- -二氫-咪唑並 喹啉- -基 -苯基 -丙腈之甲苯磺酸鹽晶體Info
- Publication number
- HK1132739A1 HK1132739A1 HK10100151.3A HK10100151A HK1132739A1 HK 1132739 A1 HK1132739 A1 HK 1132739A1 HK 10100151 A HK10100151 A HK 10100151A HK 1132739 A1 HK1132739 A1 HK 1132739A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- quinolin
- methyl
- propionitrile
- imidazo
- dihydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86648306P | 2006-11-20 | 2006-11-20 | |
| PCT/US2007/084893 WO2008064093A2 (en) | 2006-11-20 | 2007-11-16 | Salts and crystal forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1132739A1 true HK1132739A1 (zh) | 2010-03-05 |
Family
ID=39345299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK10100151.3A HK1132739A1 (zh) | 2006-11-20 | 2010-01-08 | -甲基- -甲基- -酮- -喹啉- -基- -二氫-咪唑並 喹啉- -基 -苯基 -丙腈之甲苯磺酸鹽晶體 |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US8436177B2 (zh) |
| EP (2) | EP2094700B1 (zh) |
| JP (2) | JP5562033B2 (zh) |
| KR (3) | KR20140091718A (zh) |
| CN (5) | CN109970735A (zh) |
| AR (1) | AR064256A1 (zh) |
| AU (1) | AU2007323820B2 (zh) |
| BR (1) | BRPI0719112A2 (zh) |
| CA (1) | CA2669199C (zh) |
| CL (1) | CL2007003316A1 (zh) |
| CO (1) | CO6382134A2 (zh) |
| CR (1) | CR10757A (zh) |
| DO (1) | DOP2009000116A (zh) |
| EA (1) | EA015677B1 (zh) |
| EC (1) | ECSP099340A (zh) |
| GE (1) | GEP20125436B (zh) |
| GT (1) | GT200900133A (zh) |
| HK (1) | HK1132739A1 (zh) |
| HR (1) | HRP20140627T1 (zh) |
| IL (2) | IL198467A (zh) |
| JO (1) | JO2903B1 (zh) |
| MA (1) | MA30967B1 (zh) |
| MX (1) | MX2009005360A (zh) |
| MY (1) | MY150216A (zh) |
| NI (1) | NI200900091A (zh) |
| NO (1) | NO20092227L (zh) |
| NZ (1) | NZ576357A (zh) |
| PE (2) | PE20120083A1 (zh) |
| PH (1) | PH12013502100A1 (zh) |
| RS (1) | RS53335B (zh) |
| SM (1) | SMP200900041B (zh) |
| TN (1) | TN2009000191A1 (zh) |
| TW (2) | TW201402567A (zh) |
| UA (1) | UA98473C2 (zh) |
| UY (1) | UY30728A1 (zh) |
| WO (1) | WO2008064093A2 (zh) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101897881B1 (ko) | 2008-01-04 | 2018-09-12 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| CA2717948C (en) * | 2008-03-26 | 2016-09-06 | Novartis Ag | 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes |
| US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
| CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
| JP5596137B2 (ja) | 2009-06-04 | 2014-09-24 | ノバルティス アーゲー | １Ｈ−イミダゾ［４，５−ｃ］キノリノン誘導体 |
| BR112012019459A2 (pt) | 2010-02-03 | 2017-10-17 | Signal Pharm Llc | identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase. |
| ES2593256T3 (es) | 2010-05-21 | 2016-12-07 | Infinity Pharmaceuticals, Inc. | Compuestos químicos, composiciones y métodos para las modulaciones de cinasas |
| DE102010035744A1 (de) * | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| US8901133B2 (en) | 2010-11-10 | 2014-12-02 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3581574A1 (en) | 2011-01-10 | 2019-12-18 | Infinity Pharmaceuticals, Inc. | A composition for oral administration for use in the treatment of cancer, an inflammatory disease or an auto-immune disease |
| JP6027611B2 (ja) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環式化合物及びその使用 |
| CN103930422A (zh) | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| CN103998442B (zh) | 2011-08-29 | 2016-09-14 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| JP2014532057A (ja) * | 2011-09-30 | 2014-12-04 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 粘表皮癌を治療する方法 |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9499561B2 (en) | 2012-04-10 | 2016-11-22 | Shanghai Yingli Pharmaceutical Co., Ltd. | Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| NZ708563A (en) | 2012-11-01 | 2019-02-22 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| MY181085A (en) * | 2013-03-21 | 2020-12-17 | Novartis Ag | Combination therapy |
| NZ629332A (en) | 2013-04-17 | 2017-05-26 | Signal Pharm Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| KR20160002792A (ko) | 2013-04-17 | 2016-01-08 | 시그날 파마소티칼 엘엘씨 | 암 치료용 tor 키나제 억제제 및 n-(3-(5-플루오로-2-(4-(2-메톡시에톡시)페닐아미노)피리미딘-4-일아미노)페닐)아크릴아미드를 포함하는 병용 요법 |
| BR112015026257B1 (pt) | 2013-04-17 | 2022-12-20 | Signal Pharmaceuticals, Llc | Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit |
| JP2016516815A (ja) | 2013-04-17 | 2016-06-09 | シグナル ファーマシューティカルズ，エルエルシー | １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オンに関する医薬製剤、プロセス、固形形態、及び使用方法 |
| NZ629411A (en) | 2013-04-17 | 2017-06-30 | Signal Pharm Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| EP2986321A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer |
| CA3143529A1 (en) | 2013-05-29 | 2014-12-04 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| JP6441910B2 (ja) | 2013-09-30 | 2018-12-19 | シャンハイ インリ ファーマシューティカル カンパニー リミティド | 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用 |
| EP3964507A1 (en) | 2013-10-04 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN106831721B (zh) | 2013-10-16 | 2019-10-22 | 上海璎黎药业有限公司 | 稠合杂环化合物、其制备方法、药物组合物和用途 |
| JP6701088B2 (ja) | 2014-03-19 | 2020-05-27 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物 |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| JP2017511367A (ja) | 2014-04-16 | 2017-04-20 | シグナル ファーマシューティカルズ，エルエルシー | １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法 |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN107847491A (zh) | 2015-05-20 | 2018-03-27 | 诺华公司 | 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合 |
| EP3350183B1 (en) | 2015-09-14 | 2025-04-02 | Twelve Therapeutics, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| BR112018077021A2 (pt) | 2016-06-24 | 2019-04-02 | Infinity Pharmaceuticals, Inc. | terapias de combinação |
| BR112019010470A2 (pt) | 2016-11-23 | 2019-09-10 | Novartis Ag | métodos de realce de resposta imune com everolimo, dactolisib ou ambos |
| CN110996955A (zh) | 2017-06-22 | 2020-04-10 | 细胞基因公司 | 以乙型肝炎病毒感染为特征的肝细胞癌的治疗 |
| US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
| CN111187181B (zh) * | 2019-11-22 | 2023-05-05 | 吉林大学 | 一种2-(4-氨基苯基)-2-甲基丙腈化合物的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | １ｈ―イミダゾピリジン誘導体 |
| GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
| AU2004295061B2 (en) * | 2003-11-21 | 2008-11-20 | Novartis Ag | 1H-imidazoquinoline derivatives as protein kinase inhibitors |
| AR046845A1 (es) * | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
| WO2006000020A1 (en) | 2004-06-29 | 2006-01-05 | European Nickel Plc | Improved leaching of base metals |
| GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
-
2007
- 2007-11-16 NZ NZ576357A patent/NZ576357A/en not_active IP Right Cessation
- 2007-11-16 CN CN201910073048.8A patent/CN109970735A/zh active Pending
- 2007-11-16 CN CN2012102686473A patent/CN102993202A/zh active Pending
- 2007-11-16 BR BRPI0719112-0A patent/BRPI0719112A2/pt not_active IP Right Cessation
- 2007-11-16 GE GEAP200711260A patent/GEP20125436B/en unknown
- 2007-11-16 CN CN2011103337901A patent/CN102336752A/zh active Pending
- 2007-11-16 KR KR1020147014039A patent/KR20140091718A/ko not_active Ceased
- 2007-11-16 EP EP07864492.9A patent/EP2094700B1/en active Active
- 2007-11-16 CA CA2669199A patent/CA2669199C/en not_active Expired - Fee Related
- 2007-11-16 AR ARP070105114A patent/AR064256A1/es unknown
- 2007-11-16 CN CNA2007800420773A patent/CN101541793A/zh active Pending
- 2007-11-16 KR KR1020097010203A patent/KR20090080530A/ko not_active Application Discontinuation
- 2007-11-16 US US12/514,976 patent/US8436177B2/en active Active
- 2007-11-16 JP JP2009537381A patent/JP5562033B2/ja not_active Expired - Fee Related
- 2007-11-16 MY MYPI20091920A patent/MY150216A/en unknown
- 2007-11-16 WO PCT/US2007/084893 patent/WO2008064093A2/en active Application Filing
- 2007-11-16 KR KR1020147029446A patent/KR20140129396A/ko not_active Ceased
- 2007-11-16 UA UAA200905006A patent/UA98473C2/ru unknown
- 2007-11-16 EA EA200900638A patent/EA015677B1/ru not_active IP Right Cessation
- 2007-11-16 MX MX2009005360A patent/MX2009005360A/es active IP Right Grant
- 2007-11-16 CN CN201610405653.7A patent/CN106045993A/zh active Pending
- 2007-11-16 EP EP10176298A patent/EP2364981A1/en not_active Withdrawn
- 2007-11-16 AU AU2007323820A patent/AU2007323820B2/en not_active Ceased
- 2007-11-16 RS RS20140278A patent/RS53335B/en unknown
- 2007-11-19 TW TW102134663A patent/TW201402567A/zh unknown
- 2007-11-19 CL CL200703316A patent/CL2007003316A1/es unknown
- 2007-11-19 PE PE2011001508A patent/PE20120083A1/es not_active Application Discontinuation
- 2007-11-19 JO JO2007482A patent/JO2903B1/en active
- 2007-11-19 TW TW096143742A patent/TWI417292B/zh not_active IP Right Cessation
- 2007-11-19 PE PE2007001607A patent/PE20081780A1/es not_active Application Discontinuation
- 2007-11-20 UY UY30728A patent/UY30728A1/es not_active Application Discontinuation
-
2009
- 2009-04-29 CR CR10757A patent/CR10757A/es unknown
- 2009-04-30 IL IL198467A patent/IL198467A/en not_active IP Right Cessation
- 2009-05-15 TN TNP2009000191A patent/TN2009000191A1/fr unknown
- 2009-05-18 NI NI200900091A patent/NI200900091A/es unknown
- 2009-05-18 GT GT200900133A patent/GT200900133A/es unknown
- 2009-05-18 CO CO09050683A patent/CO6382134A2/es active IP Right Grant
- 2009-05-18 EC EC2009009340A patent/ECSP099340A/es unknown
- 2009-05-19 DO DO2009000116A patent/DOP2009000116A/es unknown
- 2009-05-28 SM SM200900041T patent/SMP200900041B/it unknown
- 2009-06-03 MA MA31947A patent/MA30967B1/fr unknown
- 2009-06-09 NO NO20092227A patent/NO20092227L/no not_active Application Discontinuation
-
2010
- 2010-01-08 HK HK10100151.3A patent/HK1132739A1/zh not_active IP Right Cessation
-
2012
- 2012-05-17 IL IL219877A patent/IL219877A0/en unknown
-
2013
- 2013-04-04 US US13/856,458 patent/US20130289064A1/en not_active Abandoned
- 2013-05-13 JP JP2013101604A patent/JP2013173788A/ja active Pending
- 2013-10-10 PH PH12013502100A patent/PH12013502100A1/en unknown
-
2014
- 2014-07-01 HR HRP20140627TT patent/HRP20140627T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1132739A1 (zh) | -甲基- -甲基- -酮- -喹啉- -基- -二氫-咪唑並 喹啉- -基 -苯基 -丙腈之甲苯磺酸鹽晶體 | |
| IL206820A0 (en) | 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors and their syntheses | |
| HK1138589A1 (en) | Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors | |
| IL211148A0 (en) | 3h-imidazo [4,5-c] pyridine-6-carboxamides as anti-inflammatory agents | |
| EP1888578B8 (en) | 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo [4,5-c] quinolinyl)-phenyl]propionitrile as lipid kinase inhibitor | |
| ZA201004524B (en) | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use | |
| WO2006071862A3 (en) | Polymorphs of 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate | |
| IL195957A0 (en) | Pyrido [2,3-b]pyrazine derivatives useful as herbicidal compounds | |
| EP2142543B8 (en) | Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer | |
| EP2142544B8 (en) | Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer | |
| ZA201004023B (en) | 7-azaindole derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | |
| ZA200909132B (en) | 6-Phenyl-1H-Imidazo[4,5-C]Pyridine-4-Carbonitrile derivatives as cathepsin inhibitors | |
| SI2125714T1 (sl) | Hidrokloridna sol 5-(3-(3-hidroksifenoksi)azetidin-1-il)-5-metil-2,2-difenilheksanamida | |
| GB0714815D0 (en) | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20171116 |